SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act 1934
Date of Report: July 12, 2004
Titan Pharmaceuticals, Inc.
(Exact name of registrant as specified in
charter)
Delaware
(State or other jurisdiction of
incorporation)
|
0-27436 |
94-3171940 |
|
|
(Commission File Number) |
(IRS Employer Identification No.) |
|
|
400 Oyster Point Blvd., Suite 505, South San Francisco, CA 94080 |
||
|
(Address of principal executive offices) (Zip Code) |
||
Registrant's telephone number, including area code: 650-244-4990
Item 5. Other Events and Required FD Disclosure
On July 12, 2004, the registrant announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for Spheramine for the treatment of advanced Parkinson's disease.
A copy of the press release dated July 12, 2004 is filed herewith as Exhibit 99.1.
Item 7. Financial Statements, Pro Forma Financial Information and Exhibits
(c) Exhibits
|
Exhibit No. |
Description |
|
|
99.1 |
Press Release issued July 12, 2004. |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
TITAN PHARMACEUTICALS, INC. |
|
|
By: |
/s/ Robert E. Farrell |
|
|
Robert E. Farrell, Executive Vice President |
||
Dated: July 12, 2004
EXHIBIT INDEX
|
Exhibit No. |
Description |
|
|
99.1 |
Press Release issued July 12, 2004. |